Valproic Acid Enhances Radiosensitization <i>via</i> DNA Double-strand Breaks for Boronophenylalanine-mediated Neutron Capture Therapy in Melanoma Cells

Lai, Zih-Yin; Li, Ding-Yu; Huang, Chu-Yu; Tung, Ken; Yang, Chung-Chi; Li, Hongming; Chou, Fong‐In; Chuang, Yung-Jen

doi:10.21873/anticanres.15828

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar observation was recently described by Lai et al in murine melanoma B16-F10 cells pre-treated with VPA and then irradiated. The combination treatment significantly inhibited the growth of melanoma cells, increasing DNA DSBs, thus demonstrating that VPA can serve as a radiosensitizer in the treatment of melanoma [ 213 ]. VPA has been also shown to exert a dose-dependent growth inhibition and to trigger apoptosis at high doses in G-361 human melanoma cell line [ 214 ].…”

Section: Aeds In Other Tumor Typesmentioning

confidence: 99%

From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer

Pellegrino

Ricci

Ceraldi

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer is a major health burden worldwide. Although the plethora of molecular targets identified in the last decades and the deriving developed treatments, which significantly improved patients’ outcome, the occurrence of resistance to therapies remains the major cause of relapse and mortality. Thus, efforts in identifying new markers to be exploited as molecular targets in cancer therapy are needed. This review will first give a glance on the diagnostic and therapeutic significance of histone deacetylase (HDAC) and voltage gated ion channels (VGICs) in cancer. Nevertheless, HDAC and VGICs have also been reported as molecular targets through which antiepileptic drugs (AEDs) seem to exert their anticancer activity. This should be claimed as a great advantage. Indeed, due to the slowness of drug approval procedures, the attempt to turn to off-label use of already approved medicines would be highly preferable. Therefore, an updated and accurate overview of both preclinical and clinical data of commonly prescribed AEDs (mainly valproic acid, lamotrigine, carbamazepine, phenytoin and gabapentin) in breast, prostate, brain and other cancers will follow. Finally, a glance at the emerging attempt to administer AEDs by means of opportunely designed drug delivery systems (DDSs), so to limit toxicity and improve bioavailability, is also given.

show abstract

Section: Aeds In Other Tumor Typesmentioning

confidence: 99%

From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer

Pellegrino

Ricci

Ceraldi

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The neutrons of THOR BNCT are monitored by a LabView based PC-program OMS-BNCT that was previously developed in 2006 [ 7 , 8 ]. Recently, a lot of BNCT irradiations for head and neck cancer and brain tumor clinical treatment [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ], animal models of hepatoma study [ 20 , 21 , 22 , 23 , 24 , 25 ], studies targeting specific agents [ 26 , 27 ], or cell study of hepatocellular carcinoma, liver cancer, and melanoma [ 28 , 29 , 30 ] have been carried out at THOR. To upgrade the data acquisition capability and system hardware of the BNCT facility of to meet the requirements of users, an advanced platform with on-line monitoring, precise transmission, high storage rate, and data analysis ability is crucial.…”

Section: Introductionmentioning

confidence: 99%

NeuTHOR Station—A Novel Integrated Platform for Monitoring BNCT Clinical Treatment, Animal and Cell Irradiation Study at THOR

Huang

Peir

et al. 2023

Life

Self Cite

View full text Add to dashboard Cite

(1) Background: A well-established Boron Neutron Capture Therapy (BNCT) facility includes many essential systems, which are the epithermal neutron beam system, on-line monitoring system (OMS), QA/QC (quality assurance or quality control) system, boron concentration (BC) measurement system, and treatment planning system (TPS). Accurate data transmission, monitoring, and deposition among these systems are of vital importance before, during, and after clinical, animal, and cell BNCT irradiation. This work developed a novel integrated platform NeuTHOR Station (NeuTHORS) for BNCT at Tsing Hua Open-pool Reactor (THOR). Apart from the data of the OMS and QA/QC system, the data of BC and TPS can be loaded on NeuTHORS before BNCT clinical, animal, and cell irradiation. (2) Methods: A multi-paradigm computer programming language c# (c sharp) was used to develop the integrated platform NeuTHORS. The design of NeuTHORS is based on the standard procedures of BNCT treatment or experiment at THOR. Moreover, parallel testing with OMS-BNCT (the former OMS) and QA/QC of THOR was also performed for more than 70 times to verify the validation of NeuTHORS. (3) Results: According to the comparisons of the output, NeuTHORS and OMS-BNCT and QA/QC of THOR show very good consistency. NeuTHORS is now installed on an industrial PC (IPC) and successfully performs the monitoring of BNCT Treatment at THOR. Patients’ f BC and TPS data are also input into NeuTHORS and stored on IPC through an internal network from BC measurement room and TPS physicist. Therefore, the treatment data of each patient can be instantaneously established after each BNCT treatment for further study on BNCT. NeuTHORS can also be applied on data acquisition for a BNCT-related study, especially for animal or cell irradiation experiments. (4) Conclusions: A novel integrated platform NeuTHOR Station for monitoring BNCT clinical treatment and animal and cell irradiation study has been successfully established at THOR. With this platform, BNCT radiobiology investigations will be efficiently performed and a thorough data storage and analysis system of BNCT treatments or experiments can thus be systematically built up for the further investigation of BNCT at THOR.

show abstract

Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises

Anestopoulos

Kyriakou

Tragkola

et al. 2022

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Valproic Acid Enhances Radiosensitization via DNA Double-strand Breaks for Boronophenylalanine-mediated Neutron Capture Therapy in Melanoma Cells

Cited by 5 publications

References 0 publications

From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer

From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer

NeuTHOR Station—A Novel Integrated Platform for Monitoring BNCT Clinical Treatment, Animal and Cell Irradiation Study at THOR

Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises

Contact Info

Product

Resources

About